hero image
Dr. Amit  Oza - University Health Network. Toronto, ON, CA

Dr. Amit Oza Dr. Amit  Oza

Medical Oncology | University Health Network

Toronto, ON, CANADA

Developing, assessing and validating novel therapeutic strategies for cancer





loading image loading image


Dr. Amit Oza - We Are the Change: A Focus on Women's Cancers




Dr. Amit Oza is a Senior Staff Physician and Associate Professor of Medicine at Princess Margaret Hospital, University of Toronto. He is a Scientist with the Ontario Cancer Institute and cross appointed to the Department of Obstetrics and Gynecology at the University of Toronto. He graduated from St. Bartholomew's Hospital, University of London (UK), in 1983 and completed his internal medicine and medical oncology training in UK. He completed Clinical Research Fellowships at St. Bartholomew's Hospital/Imperial Cancer Research Fund, London (UK), Princess Margaret Hospital, Toronto and at the Netherlands Cancer Institute, Amsterdam. His postgraduate research thesis was on Molecular Epidemiology of Hodgkin's Disease. He is a Fellow of the Royal College of Physicians of London and Canada.

Dr. Oza has been the principal investigator and co-investigator in phase I, II, and III trials for gynecological cancer and advanced colorectal malignancies. His research interests are focused towards the development, assessment and validation of novel therapeutic strategies for cancer including molecular targeted therapies. Many of these studies also incorporate novel endpoints and translational research which is developed in close relationship with scientists and pathologists from the OCI/PMH.

Dr. Oza has been the recipient of various awards such as the University of Toronto Award for Teaching Excellence for the Medical Oncology Training Program, the Hasselback Award for Teaching Excellence from Princess Margaret Hospital and many others. He has also been principal and co-author of numerous publications in major peer reviewed journals such as Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Investigational New Drugs and Clinical Cancer Research.

He is currently Co-Director of the Robert and Maggie Bras and Family Drug Development Program at Princess Margaret Hospital. This is the largest new drug development program in Canada and the only center outside the US to have a contract with the NIH for Early Phase Therapeutic studies. He is also Co-Chair of the Gynecology Site Committee of the NCIC Clinical Trials Group and represents NCIC CTG at the Gynecologic Cancer Inter Group.

Industry Expertise (7)

Health and Wellness


Training and Development

Health Care - Services

Health Care - Providers

Health Care - Facilities


Areas of Expertise (6)

Gynecological Cancer

Colorectal Cancer

Cancer Therapy

Molecular Epidemiology

Clinical Research


Accomplishments (2)

Award for Teaching Excellence (professional)


Awarded by the University of Toronto for his teaching in the Medical Oncology Training Program

Hasselback Award (professional)


Awarded by the Princess Margaret Hospital

Education (1)

University of London: B.Sc. (Hons), M.B., B.S., M.D. (Lon), FRCPC, FRCP, Medicine 1983

Affiliations (5)

  • Royal College of Physicians of London and Canada : Fellow
  • Robert and Maggie Bras and Family Drug Development Program : Co-Director
  • NCIC Clinical Trials Group : Gynecology Site Committee
  • Gynecologic Cancer Inter Group : NCIC CTG Representative
  • Ozmosis Research : CEO

Media Appearances (4)

Princess Margaret joins hands with Tata Memorial

CanIndia  online


At the end of May Princess Margaret Cancer Centre, University Health Network, Toronto and Tata Memorial Centre in Mumbai signed a Memorandum of Understanding (MOU) to pool their cancer knowledge and resources. Can-India spoke with Dr. Amit Oza (Medical Oncologist and Senior Staff Physician, Princess Margaret Cancer Centre, University Health Network (UHN) and Professor of Medicine, University of Toronto), and Senthil Muthuswamy, PhD (Senior Scientist, Princess Margaret Cancer Center, The Campbell Family Institute for Breast Cancer Research, UHN ) who were both instrumental in formalizing this collaboration...

view more

Dr. Amit Oza on cancer treatment breakthrough

GlobalToronto  online


Wed, Jun 19: Dr. Amit Oza joins The Morning Show to discuss how researchers have developed a new “sharp-shooter” drug they hope may be a breakthrough in treating several types of cancer...

view more

Avastin use in ovarian cancer may delay disease

CBC  online


"This is the first new drug in ovarian cancer in 15 years to improve outcome and I believe it should be considered as a potential new standard of care," said Dr. Amit Oza, a medical oncologist who leads the Cancer Clinical Research Unit at Princess Margaret Hospital in Toronto, in a release. Oza led the study with Timothy Perren of the St. James Institute of Oncology in Leeds, England...

view more

The Princess Margaret Receives Three Awards from Cancer Care Ontario

The Campbell Family Cancer Research Institute  online


The following investigators from The Princess Margaret have received peer-reviewed Applied Cancer Research Unit Awards from Cancer Care Ontario. In commenting on these awards, Dr. Mary Gospodarowicz, Director of The Princess Margaret's Cancer Program said, "The work of all these recognized investigators has been financially supported by The Princess Margaret Hospital Foundation, in the past, and this is an excellent example of how that support has been leveraged to acquire additional funding."

view more

Event Appearances (3)

Serum activinA and TGF-β as biomarkers of breast cancer bone metastasis behavior

ASCO Annual Meeting  Chicago, IL.



Best of Oncology Conference  Toronto, ON.


Focus on Ovarian Cancer

10th Princess Margaret Hospital Conference  Toronto, ON.


Articles (5)

A phase 3 trial of bevacizumab in ovarian cancer New England Journal of Medicine


A total of 1528 women from 11 countries were randomly assigned to one of the two treatment regimens. Their median age was 57 years; 90% had epithelial ovarian cancer, 69% had a serous histologic type, 9% had high-risk early-stage disease, 30% were at high risk for ...

view more

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia Journal of Clinical Oncology


Vascular endothelial growth factor (VEGF) plays an important role in the biology of ovarian cancer (OC). Inhibitors of VEGF suppress tumor growth in OC models. Metronomic chemotherapy, defined as frequent administration of low doses of cytotoxic chemotherapy, ...

view more

Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial Journal of Clinical Oncology


In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL). Patients and Methods: Patients with metastatic ...

view more

The statins as anticancer agents Clinical Cancer Research


3-Hydroxy-3-methylgutaryl CoA reductase inhibitors, commonly referred to as the statins, have proven therapeutic and preventative effects in cardiovascular diseases. Recently, there are emerging interests in their use as anticancer agents based on ...

view more

Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiologic Reviews


There is now a large amount of evidence showing that mammographic densities are an indicator of increased risk of breast cancer. There is as yet no generally agreed upon and recognized method of classifying these densities, although the available evidence shows ...

view more